Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 27

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 27
---
 of £0.00005 nominal
value each into one Ordinary Share of £0.000001 nominal value and 49 D deferred shares of £0.000001 nominal value each.

On July 31, 2025, we effected
a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 10,000 Ordinary Shares per Depositary Share
to 100,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

Options

We
have established the Biodexa Pharmaceuticals PLC Enterprise Management Incentive and Unapproved Option Scheme, or the Plan, to allow us to grant options to purchase Ordinary Shares (in the form of Depositary Shares) to employees and directors of the Company or any of its subsidiaries for the purpose of attracting, rewarding and retaining such persons. The Plan was originally adopted in December 2014 and amended on April 11, 2024 to govern the grant of tax-advantaged enterprise management incentive stock options and unapproved stock options by the Company. As of June 30, 2025, there were options to purchase 313,070,788 Ordinary Shares. The options
lapse after ten years from the date of the grant. As of June 30, 2025, the weighted average remaining life of the options was 8.7 years.

In
connection with our acquisition of DARA in December 2015, we assumed all of DARA’s outstanding options, or DARA Options. As of
June 30, 2025 there were outstanding DARA Options to purchase six Ordinary Shares with a weighted average remaining life of 0.3 years.

Warrants

May 2020 Warrants

In May 2020, we completed
a private placement with certain institutional investors, or the May Private Placement, where we issued warrants to certain investors,
or the May Private Placement Warrants. The following is a brief summary of the May Private Placement Warrants , and is subject in all
respects to the provisions contained in the warrants, which are filed as exhibits to our Report on Form 6-K dated May 20, 2020. All other
warrants issued in the May Private Placement have expired.

| 16 |

Exercisability.The
warrants became exercisable upon issuance. The warrants will expire on November 20, 2025.

Cashless Exercise. If there is no effective registration statement registering, or no current prospectus available for, the resale of the Depositary